Warning letter
Baptist Medical Center [ARCHIVED]: warning letter of May 14, 2009
FDA warning letter 49039 · Dallas District Office
Key facts
| Reference number | 49039 |
|---|---|
| Company | Baptist Medical Center [ARCHIVED] |
| Subject | CGMP for Blood & Blood Components/Adulterated |
| Issue date | May 14, 2009 |
| Posted date | May 14, 2009 |
| Issuing office | Dallas District Office |
| Product type | Biologics |
| CFR sections cited | 606.60(a), 606.100(b)(8), 606.100(c), 606.140(c), 606.100(b) |
| Inspection city | San Antonio |
| Inspection ZIP | 78205 |
| Inspection start date | Mar 23, 2009 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: